Alzheimer's disease is a progressive neurodegenerative disease and the most common type of dementia. One of AD hallmarks is the deposition of amyloid [beta] (A-[beta]), a peptide generated from proteolytic processing of its precursor, amyloid precursor protein (APP). Canonical APP proteolysis occurs via [alpha]-/ [beta]- and [gamma]-secretases. APP is also actively degraded by protein degradation systems. By pharmacologically inhibiting protein degradation with ALLN, we observed an accumulation of heretofore undocumented APP fragments (CTFs). The two major novel CTFs migrated around 15 and 25 kD. The process was independent of cytotoxicity or protein synthesis. The build-up of the novel CTFs are not mediated by proteasome or calpain inhibition, but by cathepsin inhibition. Moreover, these novel CTFs are not generated by increased amount of BACE. Here, we name the CTF of 25 kD as [eta]-CTF. Our data suggests that under physiological conditions, a subset of APP undergoes alternative processing and the intermediate products, the 15 kD- and the 25 kD-CTFs ([eta]-CTF) get rapidly degraded/ processed via the protein degradation machinery, specifically, cathepsin.
Metrics
12 File views/ downloads
12 Record Views
Details
Title
Inhibition of protein degradation induces accumulation of novel fragments of amyloid precursor protein (APP)
Creators
Haizhi Wang
Contributors
Aleister Saunders (Advisor) - Drexel University, Drexel University (1970-)
Awarding Institution
Drexel University
Degree Awarded
Doctor of Philosophy (Ph.D.)
Publisher
Drexel University; Philadelphia, Pennsylvania
Number of pages
xii, 134 pages
Resource Type
Dissertation
Language
English
Academic Unit
College of Medicine; Neurology; Drexel University
Other Identifier
991021888997804721
Research Home Page
Browse by research and academic units
Learn about the ETD submission process at Drexel
Learn about the Libraries’ research data management services